Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”
Genetic testing for cardiovascular disorders is rapidly changing. Recent advancements in technology with next-generation sequencing and the ability to sequence more for less has provided more efficient and cost-effective patient care.
Genetic testing is like security-camera video footage of a break-in, providing essential clues to identify a culprit. In certain cancers, the “culprit” might be a rearrangement in a person’s DNA, which genomic testing can capture. Mayo Clinic has developed a novel group of clinical tests that zoom in on a person’s genome to characterize chromosomal rearrangements.
High-sensitivity troponin T is a new assay recently approved by the U.S. Food and Drug Administration. This assay is most often used to evaluate patients with possible acute ischemic heart disease, but it also has a variety of uses in the more chronic setting.
There are many probable causes of chronic diarrhea and abdominal pain, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, infectious GI pathogens, and malignancy. After excluding other causes of chronic diarrhea, a physician is left with the diagnosis IBS-diarrhea (IBS-D). One main cause of IBS-D is bile acid malabsorption.